Results 51 to 60 of about 12,412 (210)

Bullous acral eruption related to secukinumab [PDF]

, 2019
Skin reactions related to secukinumab are uncommon. Although the initial phase 3 studies of this medication reported infection and urticaria as adverse cutaneous events, other cases of unique adverse events have since been reported.
Dupuy, Elizabeth, Blackcloud, Paul, Kang, Yuna, Smart, Chandra, Hsiao, Jennifer   +4 more
core   +1 more source

Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

Therapeutic Advances in Chronic Disease, 2019
Background: Little is known about the treatment outcomes of secukinumab in clinical practice, which differ from those in clinical trials. The effectiveness of biologics may differ in psoriasis patients with previous biologics exposure.
Tzong-Yun Ger, Yu-Huei Huang, Rosaline Chung-yee Hui, Tsen-Fang Tsai, Hsien-Yi Chiu   +4 more
doaj   +1 more source

Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial

Therapeutic Advances in Musculoskeletal Disease, 2021
Background: This study aimed to evaluate the efficacy and safety of secukinumab 150 mg compared with placebo in the management of spinal pain and disease activity in patients with axial spondyloarthritis (axSpA) at Week 8 and up to Week 24.
Denis Poddubnyy, Effie Pournara, Agnieszka Zielińska, Asta Baranauskaite, Alejandro Muñoz Jiménez, Sanchayita Sadhu, Barbara Schulz, Michael Rissler, Chiara Perella, Helena Marzo-Ortega   +9 more
doaj   +1 more source

Impact of Dual Interleukin‐17A and Interleukin‐17F Inhibition with Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: MRI and Radiographic Outcomes from the Phase 3 BE MOBILE 1 and 2 Studies and their Open‐Label Extension

Arthritis &Rheumatology, Accepted Article.
Objectives To evaluate the impact of bimekizumab, a dual IL‐17A and IL‐17F inhibitor, on sacroiliac joint (SIJ) and spine inflammation/structural damage in axSpA using MRIs/radiographs from the phase 3 studies BE MOBILE 1 (nr‐axSpA) and 2 (r‐axSpA) and their open‐label extension (OLE).
Walter P. Maksymowych, Sofia Ramiro, Denis Poddubnyy, Xenofon Baraliakos, Robert G.W. Lambert, Ute Massow, Tom Vaux, Chetan Prajapati, Alexander Marten, Natasha de Peyrecave, Mikkel Østergaard   +10 more
wiley   +1 more source

Shared and Distinguishing Features of Late‐Onset Rheumatic Diseases Fulfilling Polymyalgia Rheumatica Classification Criteria

Arthritis &Rheumatology, Accepted Article.
‐
Kerem Abacar, Ala Altaie, Andrew Barr, Sarah L. Mackie, Kulveer Mankia, Dennis McGonagle   +5 more
wiley   +1 more source

Early diagnosis of axial spondyloarthritis is associated with less long‐term spinal structural damage: a longitudinal analysis of the Swiss Clinical Quality Management in rheumatic diseases registry

Arthritis &Rheumatology, Accepted Article.
Objectives The Assessment of SpondyloArthritis international Society recently defined early axial spondyloarthritis (axSpA) as a duration ≤2 years of axial symptoms. Previous studies have shown no significant difference in short‐term outcomes between early and established axSpA patients treated with biologic/targeted synthetic disease‐modifying anti ...
Annik Steimer, Jonas Brändli, Mauro Bachmann, Andrea Götschi, Claudia L. Rodrigues, Michael J. Nissen, Burkhard Möller, Kristina Bürki, Martin Wendiggensen, Simon Grosswiler, Michael Andor, Diana Dan, Frauke Förger, Sabine Adler, Diego Kyburz, Oliver Distler, Raphael Micheroli, Sofia Ramiro, Adrian Ciurea   +18 more
wiley   +1 more source

Secukinumab Inhibition of Interleukin-17A in patients with psoriatic arthritis [PDF]

, 2015
BACKGROUND: In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of secukinumab, an anti-interleukin-17A monoclonal antibody, in such patients.
Pricop, Luminita, FUTURE 1 Study group, the, Kirkham, B., Kirkham, Bruce, Yuan, J.C., Mpofu, Shephard, Pricop, L., Mpofu, S., Kavanaugh, Arthur, Rahman, P., Van den Bosch, Filip, Richards, H.B., FUTURE 1 Study Grp, McInnes, Iain B., Nash, P., Landewé, Robert, Mease, P.J., Richards, Hanno B, McInnes, I.B., Mease, Philip J., Rahman, Proton, Mease, Philip J, Richards, Hanno B., Nash, Peter, van der Heijde, Désirée, McInnes, Iain B, Heijde, D. van der, Kavanaugh, A., Landewe, R., Yuan, Jiacheng   +29 more
core   +1 more source

Secukinumab on Refractory Lupus Nephritis [PDF]

, 2021
Lupus nephritis (LN) is the most frequent severe organ manifestation of systemic lupus erythematosus (SLE). About 30% of patients are refractory to treatment.
Marinho, António, Costa, Rita, Salvador, Pedro, Oliveira, Pedro, Antunes, Paula   +4 more
core   +1 more source

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

Arthritis Research & Therapy, 2018
Background Secukinumab has demonstrated sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) over 2 years in the FUTURE 2 study (NCT01752634).
L. C. Coates, D. D. Gladman, P. Nash, O. FitzGerald, A. Kavanaugh, T. K. Kvien, L. Gossec, V. Strand, L. Rasouliyan, L. Pricop, K. Ding, S. M. Jugl, C. Gaillez, on behalf of the FUTURE 2 study group   +13 more
doaj   +1 more source

Successful Co‐Administration of Secukinumab and Dupilumab in a Patient With Psoriasis and Paradoxical Atopic Dermatitis

JEADV Clinical Practice, EarlyView.
ABSTRACT Paradoxical atopic dermatitis (AD) can arise during biologic therapy for psoriasis due to an immune‐axis imbalance. We describe a 47‐year‐old man who developed severe AD while receiving secukinumab, which was successfully managed with the addition of dupilumab, allowing long‐term control of both diseases.
So Yun Park, Minjung Park, Ho Eun Gwang, Narang Hong, Hye Jung Jung, Mi Youn Park, Jiyoung Ahn   +6 more
wiley   +1 more source